Slide 1: Investor Presentation
Ticker: MRIC Investor Presentation January 7th, 2016 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI c 2015 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-lookingstatements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “ant
Slide 3: MRI Interventions Opportunity
MRI Interventions Opportunity Market potential Market Potential 55,000 potential ClearPoint procedures across multiple therapies Electrode placement for deep brain stimulation NavigationSystem Laser Ablation for ablation of epileptic foci or Brain Tumors forMultiple Brain Tumor Biopsy for deep seate
Slide 4: MRI Interventions: Real Time MRI Guided Surgery
MRI Interventions: Real Time MRI Guided Surgery Firstto-markettechnologyplatformenabling altime MRI guideded surgery; Acleared, CE-marked and nd40+ ClearPoint sites Focused commercialization of neuro platform underway; recent restructuring complete Attractive razor/razorblade business model with str
Slide 5: Leadership: A History of Med Device Experience
Leadership A History of Med Device Experience Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank Gri
Slide 6: Technology: ClearPoint Neuro Navigation System
Investor Technology: ClearPointR Neuro Navigation System Navigation System consisting of Integrated Devices and Software for Real-Time, MRI Guided, Minimally Invasive Neurosurgical Procedures Visualize Verify Confirm Identify target Observe progress to target Confirm precise placement at target c 20
Slide 7: Without ClearPoint, minimally invasive neuro procedures are performed blind
Without ClearPoint, minimally invasive neuro procedures are performed “blind” Conventional Stereotactic Procedure ClearPointnt Neuro Procedure No real-time visualization Nextt generationn platform enabling realtime, MRIIguided, minimally invasive brain surgery c 2015 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Neuro Navigation System
ClearPointR Neuro Navigation System 1.5T or 3T MR Scanners, also works in intraop MRI Suites MRI Safe Disposable Components: SmartGridR and SmartFrameR Integrated ClearPoint Targeting and Trajectory Precision ClearPointR Drape provides sterile procedural field in any diagnostic or intraoperative MRI
Slide 9: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning VIDEO c 2015 MRI INTERVENTIONS, INC. | 9
Slide 10: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview SmartFrameR Trajectory Guide Trajectory Alignment & Device Insertion VIDEO SmartFrameR Hand Controller c 2015 MRI INTERVENTIONS, INC. | 10
Slide 11: ClearPoint Procedure Overview: Delivery of Neurological Therapy
ClearPoint Procedure Overview Delivery of Neurological Therapy Drug Deliveryry (1) Electrode Placement Laser Ablationn (2) VIDEO VIDEO VIDEO Drug Delivery 1 Electrode Placement Laser Ablation 2 (1)Drug Delivery -The SmartFlowR cannula received 510(k) clearance for injection of cytarabine, a chemothe
Slide 12: ClearPoint Hospital Economics
ClearPoint Hospital Economics Increase Patients Better potential patient experience provides hospitals the opportunity to reach additional patient populations that may otherwise forego surgery 65% of eligible DBS patients refuse treatment, due to fear of surgery (1) Established, Attractive Reimburse
Slide 13: Multi-Therapy MRI-Guided Navigational System
Multi-Therapy MRI-Guided Navigational System Notable Neurosurgeon Supporters Dr. Philip Starr Dr. Paul Larson Dr. Robert Gross Dr. Robert Wharen, Jr. Dr KrysBankiewicz DrRussLonser ASSFN Past President UCSF & VA Emory University Mayo Clinic - Bankiewicz Lab, UCSF OSU NIH Jacksonville Published Peer-
Slide 14: Patented Intellectual Property
Patented Intellectual Property Close to 100 issued patents around the world 40+ U.S. 50+ OUS 50+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrameR trajectory guide; o
Slide 15: Patient Impact: Martin's Story
Patient Impact Martin’s Story ClearPoint-Enabled Electrode Placement VIDEO c 2015 MRI INTERVENTIONS, INC. | 15
Slide 16: Patient Benefit: Minimally Invasive Procedure
Patient Benefit Minimally Invasive Procedure 7days after ClearPoint procedure Arrow Indicates Surgery Site ERVENTI INC. | 16
Slide 17: ClearPoint Drug Delivery
ClearPoint Drug Delivery MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered under MR-guidance* Specialized drug delivery cannula’s / catheters Conclusion: The ClearPoint system allows Real-time Convection-enhanced Delivery to be performed with a high level o
Slide 18: MRIC's Unique Opportunity for Drug Delivery
Uses other than the approved indication are limited by Federal law to investigational use. MRIC’s Unique Opportunity for Drug Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery of almost all drugs up to 98% of small molecules - Direct injection
Slide 19: The ClearPoint Difference
The ClearPoint Difference Without ClearPoint (Stereotactic) With ClearPoint Nodirectvisualization;Performedinanoperating Directhighresolutionvisualization;Performedin room an MRI Suite Accuracy to target based on prior images Highly accurate, based on real time images Patient may be awake forown bra
Slide 20: ClearPoint Revenue Model
ClearPoint Revenue Model BUSINESS MODEL RAZOR / RAZORBLADE ClearPoint Hardware/Software: $100,000 -$150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG reimb
Slide 21: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 39 sites in the US September, 2015 c 2015 MRI INTERVENTIONS, INC. | 21
Slide 22: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity Parkinson’s Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis) Prevalence Drug Treatment 125,000 264,000 Resistant (DTR) 7,500 18,000 Resections: 80,000 Incidence DTR Stereotactic Biopsy: 10,000 Electrode Laser Ablation Biopsy /
Slide 23: ClearPoint Future Opportunities
ClearPoint Future Opportunities Multiple Therapies for Future Growth Patient Treatment Resistant ClearPoint Enabled Current Status Neuro Disorder Population Patient Population Therapy Dystonia 250,000 25,000 DBS Active Use, HDE OCD 3,300,300 100,000 DBS Active Use, HDE SevereDepression 6,000,000 1,2
Slide 24: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues Consumables $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2013 2014 2015 c 2015 MRI INTERVENTIONS, INC. | 24
Slide 25: Total Revenue, 2013-2015
Total Revenue, 2013 -2015 $1,600,000 Total Revenue $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2013 2014 2015 Consumables Capital / Service Other c 2015 MRI INTERVENTIONS, INC. | 25
Slide 26: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q2 Q3 Q4 Q1 Q2 Q3 2014 2015 © 2015 MRI INTERVENTIONS, INC. | 26
Slide 27: Commercial Priorities
Commercial Priorities Focus on adding surgeons at existing accounts ncrease Target high volume sites, including epilepsy and tumor neurosurgeons within each Utilization account; gain greater share of their procedures Add Clinical Specialists and sales reps to commercial team; compensate for utilizat
Slide 28: R&D Priorities
R&D Priorities Seek significant upgrade to existing software; includes Software 2.0 real time fusion, enhanced graphic and User Interface Technology licenses near complete with three additional software companies for this effort Through partnership(s), expand our products OR SmartFrame and brand int
Slide 29: At the Center of an Emerging Industry Trend
At the Center of an Emerging Industry Trend ClearPoint ClearPoint MRICisatthepointof Electrode Laser Catheter Placement Placement convergenceinan industrytrendimpacting Real Time MRI- someofthemost ClearPoint Guided ClearPoint Direct Drug Procedures Performed influentialand Delivery in MRI innovativ
Slide 30: MRI Interventions, Inc. contact
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI c 2015 MRI INTERVENTIONS, INC. | 30